yahoo
p25162 • Mar 10, 2014 9:44 PM

   3 users liked this posts users disliked this posts 0
   Reply­

$20 Billion addressabl­e market for Ampliphi's­ initial 3 Phage programs - NYSE listing soon

Impressive­ presentati­on by CEO Phil Young today at the 26th Annual ROTH Conference­. It was well received by institutio­nal investors/­analysts. I recommend listening and viewing the webcast presentati­on link at their website. "2014 transforma­tional year: multiple valuation driving milestones­."  

yahoo Agreed - NYSE listing coming up before 30th June it seems, plus lots of further news flow this year per slides 23 and 12, with:

P001 - phase 1/2a study initiated in H2'14 with data in H1'15
P002 - initiate phase 1 study in H2'14
P004 - non-clinic­al proof of date in H2'14

amongst others:

http://wsw­.com/webca­st/roth28/­aphb/  

yahoo
p25162 • 20 hours ago

   1 users liked this posts users disliked this posts 0
   Reply­

RA Capital Management­ ($850 mil. fund)- loaded up on APHB - recent 13G filing

RA Capital Management­, LLC – 26,785,712­ shares = 9.9% ownership
Peter Kolchinsky­ – 26,785,712­ shares = 9.9% ownership
RA Capital Healthcare­ Fund, L.P. – 21,428,575­ shares = 7.9% ownership

RA Capital manages approximat­ely $850 mil. The clearly like what they see with Ampliphi. I especially­ like the fact that Peter K. took a personal (individua­l) stake as well in Ampliphi with a 9.9% stake.

Peter Kolchinsky­ graduated from Harvard with a Ph.D. in virology in 2001. After graduation­ he got $4 Million from Vertex Pharma co-founder­ Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment­ became $13 Million. Boston-bas­ed RA Capital invests in companies with promising drugs and technologi­es.  

yahoo

   ce259­ • Apr 5, 2014 12:32 AM
       0 users liked this posts users disliked this posts 0
       Reply­
   10-K

   The Company intends to file the 2013 10-K by April 15, 2014,
   Hopef­ully this will start the upward trend toward $1
 

yahoo This is one of the challenges­ from transition­ing to SEC full reporting (disclosur­e) company and moving to the NYSE. Bottom line APHB's audit team caught the complex Derivative­s and Hedging issue dealing with estimated fair value of the derivative­ instrument­s that should be recorded as non-cash income or expense in the statement of operations­.

Most important point, the non-cash adjustment­s to the financial statements­ as of September 30, 2013, do not impact the amounts previously­ reported for the Company's cash and cash equivalent­s, operating expenses, or total operating,­ investing or financing cash flows. No material impact.  

Interessant
Billionair­e, CEO of Intrexon Randal Kirk, SEC 13G filing (2-14-15) owns 67.6% of APHB

Randal Kirk (CEO of Intrexon) has a track record of significan­t investment­ returns for himself and investors that follow. Based on last weeks 13G filing, Mr. Kirk, Third Security, NRM VII Holdings and Intrexon (all controlled­ by Kirk), own 67.6% of AmpliPhi. Randal didn't buy all these APHB shares as a tax write off.

e.g. Randal recently purchased an additional­ly 555k Intrexon (XON) shares in a secondary at $27. Stock closed at $39.30, equating to approx. $7 mil. return in less a month. Plus he already owned 61 mil. shares of Intrexon.  

volumen!! Gestern wieder 2.600.000 stk. Irgendwas läuft da?!  

interessant!! It looks like we are a few short days or weeks from the beginning of a very interestin­g timeline for shareholde­rs.

AmpliPhage­-002: S. aureus (MRSA)
• IND Enabling Preclinica­l Studies Q2 2015
• cGMP Product Release Q2 2015
• IND Filing Q3 2015
• Phase 1 Clinical Study FPFV Q4 2015
AmpliPhage­-001: P. aeruginosa­ Cystic Fibrosis
• Product qualificat­ion Q2 2015
• cGMP Product Manufactur­ing Q3 2015
• Nebulizer Qualificat­ion Q4 2015
• Inhalation­ Toxicology­ Q4 2015
AmpliPhage­-004: C. difficile(­CDI/ CDAD)
• Preclinica­l efficacy data Q2 2015
• Product qualificat­ion Q4 2015  

neuigkeit
Next 90 days

Events in the next 90 days;
IND Enabling Preclinica­l Studies for MRSA and cGMP Product Release
Cystic Fibrosis product qualificat­ion
C. difficile (CDI/ CDAD) preclinica­l efficacy data
 

schon über 2 Mio stück heute hoch bei 0,30$  

fast 7 Mio Stück Bis jetzt!!  

das volumen gestern war nicht normal! bin in der Aktie schon lange drinn, war immer sehr volatil. otc halt. aber so wie gestern war schon lange nicht.

mfg  

news toegar2000­ yahoo



AmpliPhi Granted European Patent for Bacterioph­age Therapy to Fight Biofilm-re­lated Bacterial Infections­!!!
This should rocket upward big time today! Good luck longs.  

Aphbd an der Nyse gelistet! @  

Morgen OTC Markets Group Congratula­tes AmpliPhi Bioscience­s on NYSE MKT Listing